ABSTRACT Animal studies have indicated the carcinogenic potential of ethylene dibromide (EDB). Examination of the mortality experience of employees exposed to EDB in two Previous inhalation studies4 had indicated that rats exposed for up to six months to concentrations of 50 ppm EDB showed evidence of injury to the lungs, liver, kidney, and spleen. No tumours were observed in this series of six-month studies that included rabbits, monkeys, and guinea pigs, as well as rats. Studies were also conducted at 25 ppm. The authors concluded that "rabbits and monkeys and probably rats and guinea pigs can tolerate without adverse effects daily repeated seven-hour exposures to a vapour concentration of 25 ppm of ethylene dibromide."
Concern regarding the carcinogenic potential of ethylene dibromide (EDB) was raised based on the results of animal studies conducted by Olson et al.1 Of 50 rats exposed at one half the maximum tolerated dose, 40 mg/kg/day administered by intragastric tube, 49 developed squamous-cell carcinomas of the stomach. The first tumour was observed as early as 12 weeks after initial exposure. In a more recent study increased tumour incidences were reported in rats exposed to 20 parts per million (ppm) EDB by inhalation, initially in a group of rats treated with 0.050% disulfiram in the diet,2 and thereafter in the group of rats on a control diet. 3 Previous inhalation studies4 had indicated that rats exposed for up to six months to concentrations of 50 ppm EDB showed evidence of injury to the lungs, liver, kidney, and spleen. No tumours were observed in this series of six-month studies that included rabbits, monkeys, and guinea pigs, as well as rats. Studies were also conducted at 25 ppm. The authors concluded that "rabbits and monkeys and probably rats and guinea pigs can tolerate without adverse effects daily repeated seven-hour exposures to a vapour concentration of 25 ppm of ethylene dibromide." Bondi and Alumot5 found that one of two bull calves fed EDB at 10 mg/kg/day from the third day after birth showed signs of pneumonia, lack of co-ordination, and inability to stand at 5 weeks.
Received 29 August 1979 Accepted 2 October 1979 Necropsy showed severe pneumonia and a fatty infiltration of liver and kidneys in one calf. The present survey was undertaken to investigate the mortality experience of employees occupationally exposed to EDB in two manufacturing plants. The emphasis of the study was on cancer mortality and mortality due to respiratory disease.
Environmental considerations
The employees included in this investigation had worked either in an EDB manufacturing unit located in Michigan or in a second unit located in Texas. Since both of these operations have been discontinued (the Texas plant closed in 1969 and the Michigan plant in 1976), environmental assessments were based on existing records and discussions with employees formerly associated with the plants. Con Table 2 summarises the blood bromides determined for reactor and still operators between 1957 and 1970. The blood bromide concentrations ranged from 1 mg/100 ml to 17 mg/100 ml over the period, with a mean of 6 5 mg/100 ml. These findings are not specific for EDB in the presence of other process chemicals containing bromine. In addition, non-prescription medications, bromides in drinking water, and certain foods may raise blood bromide concentrations.
Method of analysis
Employees from both units were identified by reviewing annual census lists and selecting all reactor and still operators from unit 2, and lead burners, reactor and still operators, and foremen from unit 1. Of the men in unit 1, 19 had worked as lead burners. In unit 2 individuals who left the company before 1940 were not included in the study, partly because of the difficulty of conducting social security follow- 
Results
Because of limited industrial hygiene data, length of employment on the jobs of highest concern (still and reactor operators in both units, and foreman and lead burners in unit 1) was the only indicator of exposure used in the analysis. Table 4 shows duration of exposure, by year first exposed, for each manufacturing unit. Several of the men, especially in unit 2, may have held other jobs, resulting in potential low intensity EDB exposure, which would not have been included in the tabulation. Table 5 summarises observed and expected deaths, by cause, for the two production units excluding the five employees from unit 2 who had worked with arsenicals in addition to EDB. Three deaths have occurred among these five people, compared with 0-6 expected. Two of the deaths were due to respiratory cancer. One death from respiratory cancer has been reported to date among individuals exposed only to EDB. Information on cause of death has not been obtained for three of the 21 deaths in unit 1. One of these individuals died within two years of being drafted into the armed Forces and may therefore have been killed in military action. In unit 1 one person with 26 months of exposure, and whose immediate cause of death was listed as arteriosclerotic heart disease, had a metastatic carcinoma of the lymph nodes listed under other significant conditions at death (primary site undetermined).
Increased malignancy and respiratory deaths were 
